TrialActa oncologica (Stockholm, Sweden)2022

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.

Manuela Schmidinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.